Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells

Cell(2024)10.1016/j.cell.2024.01.035Source: DataRank Database

A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells is a research paper published in Cell (2024). On theSindex it has a DataRank of 0. It has been cited 115 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access115 citations

Download PDF

Cite:

Linked data & code

geo gen

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Topics (16)IDs (PubMed, PMC)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Elena Sotillo ORCID,Jeremy Bjelajac ORCID,Xingyu Chen ORCID,Meena Malipatlolla,Justin A. Guerrero

Live enrichment

PubMed:38387457 PMC:PMC10965243

NCI NIH HHS

Grant: R21 CA270609

NCI NIH HHS

Grant: P30 CA124435

NIH

National Science Foundation

CIRM

MeSH Terms

T-LymphocytesHumansRNAGene Expression ProfilingMetabolic EngineeringTranscriptome

Keywords

Cell therapymetabolic engineeringCancer ImmunotherapySynthetic BiologyCrisprGene EditingT Cell ExhaustionRna TargetingCar T CellsCas13

Related Papers (10)

In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target

Cell(2021)

co-citedsame journal

10.1016/j.cell.2021.09.006

Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer

Molecular Cell(2021)

co-cited

10.1016/j.molcel.2021.06.014

ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells

Nature Cell Biology(2021)

co-cited

10.1038/s41556-020-00624-3

CRISPR-based therapeutics: current challenges and future applications

Trends in Pharmacological Sciences(2021)

co-cited

10.1016/j.tips.2021.10.012

Genomic Alterations in PIK3CA -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors

Cancer Research(2021)

co-cited

10.1158/0008-5472.can-20-3232

Systematic functional interrogation of human pseudogenes using CRISPRi

Genome biology(2021)

co-cited

10.1186/s13059-021-02464-2

Detection of phenotype‐specific therapeutic vulnerabilities in breast cells using a CRISPR loss‐of‐function screen

Molecular Oncology(2021)

co-cited

10.1002/1878-0261.12951

High-content CRISPR screening

N/A

6.0DataRank · unranked

Nature Reviews Methods Primers(2022)

co-cited

10.1038/s43586-022-00098-7

Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models

N/A

0.482DataRank · unranked

PNAS Nexus(2022)

co-cited

10.1093/pnasnexus/pgac232

Complementary CRISPR genome-wide genetic screens in PARP10-knockout and overexpressing cells identify synthetic interactions for PARP10-mediated cellular survival

Oncotarget(2022)

co-cited

10.18632/oncotarget.28277

A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells

FAIR Checklist

Authors (12)

Funding (5 grants)

Topics

Annotations (Europe PMC)

Related Papers (10)